Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Remicade (infliximab by Year
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)
Merck Remicade (infliximab: $0M in FY2025, down 100.0% from a year earlier. That is the lowest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | -100.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 51 | -72.7% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 187 | -9.7% | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| FY2022 | Dec 31, 2022 | 207 | -30.8% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 299 | -9.4% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 330 | -19.7% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 411 | -29.4% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 582 | -30.5% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 837 | -34.0% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 1,268 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up remicade (infliximab
- Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M)0 · FY2025
- Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — International sales ($M)0 · FY2025
- Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)-36.0% · FY2024
Cite this data
StockData. (2026). Merck Remicade (infliximab ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-remicade
See every metric in the Merck KPI table. Data updated Oct 26, 2026.